Beta-o2 Technologies Ltd.

📍 Rosh Ha'ain, Israel🗓 Founded 2004👥 20 employees💰 Last funded Nov 2016
Biotechnology Research🌐 Beta-o2.com
Website LinkedIn
Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID). Patients with TID are unable to produce insulin, a hormone needed to transport sugar into cells, providing the energy needed for daily life. ßAir provides a viable and safe environment for islets of Langerhans (insulin producing beta cells), to thrive and provide the body with insulin on demand. It is able to do so, as Beta-O2 has solved the major challenges of islet transplantation – creating a protective environment where the cells can thrive but where the patient doesn’t need to take life-long immunosuppression drugs with unpleasant side effects, and of crucial importance, keeping the cells alive and functioning inside the recipient’s body.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2004
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Israel
1
Frequently asked questions
Who invested in Beta-o2 Technologies Ltd.?
Beta-o2 Technologies Ltd. has 1 investors on record on gritt.io.
When did Beta-o2 Technologies Ltd. last raise funding?
The most recent investment in Beta-o2 Technologies Ltd. recorded on gritt.io was in November 2016.
When was Beta-o2 Technologies Ltd. founded?
Beta-o2 Technologies Ltd. was founded in 2004.
What industry is Beta-o2 Technologies Ltd. in?
Beta-o2 Technologies Ltd. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Beta-o2 Technologies Ltd. based?
Beta-o2 Technologies Ltd. is headquartered in Rosh Ha'ain, Israel.